



MARYLAND
Department of Health

**MARYLAND ADVISORY BOARD ON
PRESCRIPTION DRUG MONITORING (PDMP)**

**April 9, 2019
2:30PM to 4:00 PM**

TELECONFERENCE CALL



Attendees

Advisory Board

David Sharp, PhD (Interim Chair)Amit
Bhargava, MD, MS, RMSK
Thomas Bond III
Richard DeBenedetto, PharmD, MS,
AAHIVP
Lenna Israbian-Jamgochian, PharmD, RPh
Marcus Jones
Stephen A. Nichols, MD, FAAP, FAAMR

Bonnie Oettinger, RN, MGA
Mark Olszyk, MD, MBA, CPE, FACEP,
FACHE, FFSMBOrlee Panitch, MD
Derek Peck
Larry Polsky, MD, MPH
Joseph Scalese III, RPh
Amar Setty, MD

Board Adjunct: Linda Bethman, JD, MA, Office of the Attorney General, MDH

Advisory Board Not Present

Audrey Clark, MPA (Board Chair)
Daniel M. Ashby, MS, FASHP
Arthur C. Jee, DMD
Chris Jillson, MDBrian Marascalchi, MD
Diana Shorter, DNP
Michael Vaughn

Public Health Services Staff

Tryphena Barnes
Anna Gribble, MPH, MSW
Kate Jackson, MPH
Katherine Johnson, MHA
Casey Lyons, MPH, CPH
Sara Roberson, MSW

CRISP Staff

Rhonda Moody

Leap Orbit Staff

David Finney, Partner

Minutes

I. Roll Call, Agenda Review and Approval of Minutes

Kate Jackson, PDMP Director, opened today's meeting with roll call, reviewed the topics of discussion on the agenda, and circulated a draft of last meeting's minutes for review and edits.

II. Fatal Overdose Notifications Update

Anna Gribble presented on Fatal Overdose Notifications, reviewing Subcommittee discussions and recommendations. Notification letters are designed to inform a provider about the death of a patient, offer resources to providers, and serve as an opportunity to impact prescribing/dispensing practices. The goals of Fatal Overdose Notifications are to increase the use of the PDMP and improve relationships between patients and providers.

The Subcommittee advised on scenarios that would trigger a fatal overdose notification and the content of the notification letter.

Casey Lyons provided a brief update on the data sharing relationship between PDMP and the Office of the Chief Medical Examiner (OCME) and the Vital Statistics Administration (VSA). The Program receives data on a monthly basis from OCME/VSA on drug-related deaths, from one to three months after the death occurs, depending on the time it takes the OCME to complete the investigation. The Program anticipates two to five months between the date of death and providers receiving a notification.

The PDMP Subcommittee recommends the following:

- Cause of death that would trigger a letter: illicit opioids or prescription opioids
- Providers who wrote or dispensed an opioid or a benzodiazepine prescription up to 3 months before death would receive a notification
- Prescribers and dispensers receive a notification
- Prescribers and dispensers should have access to the toxicology data
- Providers in other states should also receive notifications

Notifications will go to a pharmacy, not a pharmacist. Prescribers and dispensers will begin receiving electronic notifications in 2020. Electronic notifications will allow the Program to send additional notifications, create a more efficient mechanism for providers to offer feedback through a survey, and allow the Program to streamline the notification process. Federal funds awarded through grants will support the development of electronic notifications.

PDMP's next steps include the following activities:

- Discuss the Data Use Agreement with OCME
- Share the notification and Subcommittee recommendations with the PDMP Technical Advisory Committee (TAC)
- Finalize the matching procedure to match PDMP data with OCME data

- Discuss with Department leadership the need for a clinician to answer questions raised by Maryland providers when they receive a notification
- Develop survey questions
- Incorporate feedback from Maryland providers on the notification
- Identify a mechanism to share toxicology data with providers

The intent and tone of the notification is to alert the prescriber of possible misuse or abuse of prescription drugs by a patient, encourage increased screening for substance use disorder, and connect provider to clinically relevant resources. The content of the notification intentionally avoids placing blame or suggest a causal relationship between a providers' prescribing or dispensing decisions and an overdose death.

III. Patient Matching in RxGov (Investigative Requests) Update

During the last Advisory Board meeting the Board authorized the Program to move forward in implementing the RxGov record matching algorithm in the investigative data request workflow. Kate Jackson presented updates on the patient matching algorithm and the planned implementation.

IV. Center for Disease Control (CDC) Overdose Data to Action Grant Application

The Department is applying for a three-year grant from the CDC titled Overdose Data to Action or OD2A. This grant is a continuation of three previously awarded grants from CDC to the Maryland Department of Health. Kate Jackson and Anna Gribble presented on two components of the OD2A grant, Expanding PDMP Functionality and Provider and Health System Support. Funded activities included in the grant application for each component include:

- Expand PDMP clinical decision support tools
 - Build Prescriber Insight Reports
 - Build a PDMP Alerts Center
 - Expand electronic health record (EHR) integrations and interstate data sharing
- Improve the Program's capacity to identify potentially risky prescribing
 - Create a TAC data review system
 - Build Electronic Unsolicited Reporting Functionality
- Improve PDMP data sharing to inform public health planning:
 - Improve the CRISP tool: 'Opioid Indicator Dashboards'
- Develop and disseminate provider education resources
 - Convene and manage a Provider Engagement Policy Workgroup
 - Develop and disseminate Maryland-Specific Prescribing Guidelines
 - Implement a Statewide Academic Detailing Project
 - Offer provider trainings through a partnership with MedChi

V. Legislative Session Recap

Kate Jackson presented updates on two legislative bills that impact the PDMP, HB025 and cross filed as SB195 as well as HB466 and cross filed as SB342.

Kate Jackson urged Members to take review the Bills to ensure Board members are well versed in how the PDMP is changing. If anyone has any questions on these Bills please reach out to Kate Jackson for additional information.

Meeting Adjourned